Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marchex (MCHX) Gains from Sales and Divestitures (2016 - 2025)

Marchex (MCHX) has disclosed Gains from Sales and Divestitures for 16 consecutive years, with $270000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures fell 24.58% to $270000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $270000.0, a 24.58% decrease, with the full-year FY2024 number at $361000.0, down 32.52% from a year prior.
  • Gains from Sales and Divestitures was $270000.0 for Q3 2025 at Marchex, up from $233000.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $535000.0 in Q4 2023 to a low of $71.0 in Q1 2021.
  • A 5-year average of $160850.7 and a median of $104000.0 in 2024 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: crashed 49.05% in 2021, then soared 71072.96% in 2024.
  • Marchex's Gains from Sales and Divestitures stood at $476000.0 in 2021, then rose by 3.36% to $492000.0 in 2022, then increased by 8.74% to $535000.0 in 2023, then plummeted by 32.52% to $361000.0 in 2024, then dropped by 25.21% to $270000.0 in 2025.
  • Per Business Quant, the three most recent readings for MCHX's Gains from Sales and Divestitures are $270000.0 (Q3 2025), $233000.0 (Q2 2025), and $118000.0 (Q1 2025).